The 36-month beta value for OCGN is at 3.74. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for OCGN is 283.54M, and currently, shorts hold a 18.07% of that float. The average trading volume for OCGN on September 23, 2024 was 5.40M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
OCGN) stock’s latest price update
The stock of Ocugen Inc (NASDAQ: OCGN) has decreased by -3.60 when compared to last closing price of 1.11.Despite this, the company has seen a loss of -8.55% in its stock price over the last five trading days. seekingalpha.com reported 2024-09-17 that Ocugen continues advancing its gene therapy pipeline, with OCU400 in Phase 3 trials for retinitis pigmentosa, targeting FDA approval by 2026. OCU400 has received the FDA’s RMAT designation and is supported by an Expanded Access Program. Ocugen’s broader pipeline includes OCU410 for geographic atrophy and OCU410ST for Stargardt disease, both progressing through early trials.
OCGN’s Market Performance
OCGN’s stock has fallen by -8.55% in the past week, with a monthly drop of -13.01% and a quarterly drop of -15.08%. The volatility ratio for the week is 6.72% while the volatility levels for the last 30 days are 6.25% for Ocugen Inc The simple moving average for the last 20 days is -12.04% for OCGN’s stock, with a simple moving average of -10.33% for the last 200 days.
Analysts’ Opinion of OCGN
Many brokerage firms have already submitted their reports for OCGN stocks, with Chardan Capital Markets repeating the rating for OCGN by listing it as a “Buy.” The predicted price for OCGN in the upcoming period, according to Chardan Capital Markets is $3.50 based on the research report published on March 01, 2023 of the previous year 2023.
Mizuho, on the other hand, stated in their research note that they expect to see OCGN reach a price target of $5. The rating they have provided for OCGN stocks is “Buy” according to the report published on August 23rd, 2022.
ROTH Capital gave a rating of “Buy” to OCGN, setting the target price at $8 in the report published on June 15th of the previous year.
OCGN Trading at -21.29% from the 50-Day Moving Average
After a stumble in the market that brought OCGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.17% of loss for the given period.
Volatility was left at 6.25%, however, over the last 30 days, the volatility rate increased by 6.72%, as shares sank -17.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -42.77% lower at present.
During the last 5 trading sessions, OCGN fell by -8.03%, which changed the moving average for the period of 200-days by +176.32% in comparison to the 20-day moving average, which settled at $1.2053. In addition, Ocugen Inc saw 86.09% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OCGN starting from RAMESH KUMAR, who proposed sale 116,705 shares at the price of $1.25 back on Aug 16 ’24. After this action, RAMESH KUMAR now owns shares of Ocugen Inc, valued at $145,905 using the latest closing price.
Stock Fundamentals for OCGN
Current profitability levels for the company are sitting at:
- -6.31 for the present operating margin
- 0.86 for the gross margin
The net margin for Ocugen Inc stands at -6.21. The total capital return value is set at -2.29. Equity return is now at value -120.03, with -80.82 for asset returns.
Based on Ocugen Inc (OCGN), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -13.71. The debt to equity ratio resting at 0.2. The interest coverage ratio of the stock is -41.27.
Currently, EBITDA for the company is -64.83 million with net debt to EBITDA at 0.17. When we switch over and look at the enterprise to sales, we see a ratio of 36.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.04.
Conclusion
In conclusion, Ocugen Inc (OCGN) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
